Brief: Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data
28/02/2024 13:37
Feb 28 (Reuters) - Vivani Medical Inc VANI.O :
* VIVANI MEDICAL ANNOUNCES POSITIVE NPM-115 PRECLINICAL
WEIGHT
LOSS DATA COMPARABLE TO OZEMPIC®/WEGOVY® AND DISCLOSES NPM-139
AS SEMAGLUTIDE AS STRATEGY SHIFTS TO PRIORITIZE OBESITY
PORTFOLIO
* VIVANI MEDICAL-NPM-115 GENERATED SIGNIFICANT WEIGHT LOSS
VERSUS
INJECTABLE SEMAGLUTIDE FROM A SINGLE ADMINISTRATION WITH
EXPECTED TWICE-YEARLY DOSING
* VIVANI MEDICAL INC - DISCLOSES SEMAGLUTIDE AS ACTIVE
PHARMACEUTICAL INGREDIENT IN NPM-139, WITH ADDED POTENTIAL
BENEFIT OF ONCE-YEARLY DOSING
Source text for Eikon: ID:nBw5qgcBPa
Further company coverage: VANI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivani Medical
See all newsVivani Medical Q2 net loss narrows as expenses fall
Vivani Medical Inc reports results for the quarter ended June 30 - Earnings Summary
Vivani Medical Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia